{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:44:39Z","timestamp":1790264679671,"version":"4.1.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s163225","type":"journal-article","created":{"date-parts":[[2019,3,24]],"date-time":"2019-03-24T22:05:20Z","timestamp":1553465120000},"page":"2393-2404","source":"Crossref","is-referenced-by-count":24,"title":["<p>Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel<\/p>"],"prefix":"10.2147","volume":"Volume 11","author":[{"given":"Andreas","family":"Viardot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Wais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixten","family":"Koerper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,3]]},"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=48717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=48717","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,24]],"date-time":"2019-03-24T22:05:22Z","timestamp":1553465122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/chimeric-antigen-receptor-car-t-cell-therapy-as-a-treatment-option-for-peer-reviewed-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/cmar.s163225","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}